Navigation Links
ClinStar to Present on Conducting Clinical Trials in Russia
Date:7/21/2011

SAN FRANCISCO, July 21, 2011 /PRNewswire/ -- ClinStar, LLC, an established CRO providing clinical research services in Russia and Eastern Europe to the pharmaceutical and biotechnology industry, announced today that President and CEO David Passov will speak at Marcus Evans 6th Annual Clinical Research in Emerging Countries conference July 28-29 in Miami, FL.   

(Logo: http://photos.prnewswire.com/prnh/20110719/SF36975LOGO)

The paradigm of traditional drug development is shifting as more and more biopharmaceutical organizations look to emerging markets to reduce their clinical study timelines, and hence overall development costs, through more effective patient enrollment. During his presentation scheduled for Thursday, July 28 at 10:30 a.m., Mr. Passov will address the perceptions of emerging markets; consider the benefits of conducting clinical trials in Russia compared to other emerging countries; and explore how best to navigate the new clinical trial regulations in order to optimize clinical trial performance. Mr. Passov will also chair the first day of this year's conference.

The Marcus Evans Clinical Research in Emerging Countries conference, now in its 6th year, will offer a half day workshop on July 27 followed by two days of sessions led by pharmaceutical and biotechnology industry leaders. Marcus Evans Emerging Countries conference series is aimed at equipping industry professionals with necessary knowledge on critical globalization issues such as regulatory and legal compliance, training of personnel, overcoming cultural barriers, and clinical outsourcing opportunities.  

About ClinStar, LLC

ClinStar is one of the most prominent CROs in the emerging markets of Eastern Europe and the Baltics, with more than 10 years of expertise in Phase I-IV clinical studies in multiple therapeutic areas. Headquartered in San Francisco, California, ClinStar manages studies from its offices in Russia, Ukraine and Belarus, with total staff of over 300 people. Its portfolio contains over 130 clinical trials conducted for US and European pharmaceutical and biotechnology companies. More information is available at www.clinstar.com.


'/>"/>
SOURCE ClinStar, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ClinStar, LLC Establishes New Office on the US East Coast
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
9. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
10. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
11. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ... Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) expired ... Time). As previously announced on May 31, ... merger agreement under which Jazz Pharmaceuticals has commenced a ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... only authorized OSHA Training Institute Education Center headquartered in Northern California, has issued ... from extreme heat at their worksites. Employers with workers exposed to high ...
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... health professionals, announced today its affiliation with Tennessee Counseling Association. This ... the network of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... today announced its strategic partnership with Connance, a healthcare industry leader providing ... companies’ proven, proprietary technology combine to provide health systems, hospitals and ambulatory ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... edge technology to revolutionize the emergency ambulance transport experience for the millions of ... of how Uber has disrupted the taxi industry through the use of technology. ...
Breaking Medicine News(10 mins):